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Case-control disease-marker association studies are often used in the search for variants that predispose to complex
diseases. One approach to increasing the power of these studies is to enrich the case sample for individuals likely
to be affected because of genetic factors. In this article, we compare three case-selection strategies that use allele-
sharing information with the standard strategy that selects a single individual from each family at random. In
affected sibship samples, we show that, by carefully selecting sibships and/or individuals on the basis of allele
sharing, we can increase the frequency of disease-associated alleles in the case sample. When these cases are compared
with unrelated controls, the difference in the frequency of the disease-associated allele is therefore also increased.
We ﬁnd that, by choosing the affected sib who shows the most evidence for pairwise allele sharing with the other
affected sibs in families, the test statistic is increased by 120%, on average, for additive models with modest genotype
relative risks. In addition, we ﬁnd that the per-genotype information associated with the allele sharing–based
strategies is increased compared with that associated with random selection of a sib for genotyping. Even though
we select sibs on the basis of a nonparametric statistic, the additional gain for selection based on the unknown
underlying mode of inheritance is minimal. We show that these properties hold even when the power to detect
linkage to a region in the entire sample is negligible. This approach can be extended to more-general pedigree
structures and quantitative traits.
Introduction
Mapping studies of complex disease often involve case-
control disease-marker association studies (Risch 2000;
Cardon and Bell 2001). A sample of affected cases is
compared with a suitable control group to test for as-
sociation between allelic variants and disease status.
These studies currently are conducted in candidate genes
and linkage candidate regions and, as our understanding
of variation in the genome improves (Patil et al. 2001;
Dawson et al. 2002; Gabriel et al. 2002), soon will be
conducted genomewide. Usually, to canvass adequately
a region of interest for association, many markers must
be genotyped. The exact density of markers required to
sample the variation adequately depends on the extent
and pattern of linkage disequilibrium in the region (Abe-
casis et al. 2001; Carlson et al. 2003). In addition, be-
cause modest effect sizes are expected for loci predis-
posing to complex diseases (Risch 2000), hundreds or
even thousands of individuals may be required to obtain
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sufﬁcient power to detect association. Hence, depending
on the size of the region, association studies may require
the genotyping of hundreds of thousands of markers in
thousands of individuals. Although much progress has
been made in developing accurate, high-throughput SNP
genotyping (Sachidanandam et al. 2001; Syvanen 2001;
Oliphant et al. 2002; Olivier et al. 2002), association
studies can be costly and require substantial effort, mak-
ing efﬁcient study design important.
One strategy for improving the power of genetic stud-
ies is to select individuals who are most likely to carry
genetic risk factors. These genetically loaded individuals
or families presumably provide a stronger signal and
facilitate identiﬁcation of the variant(s) responsible for
disease. Standard designs include choosing individuals
with an early age at onset (e.g., Hall et al. 1992), a more
severe form of the disease (e.g., Goldstein et al. 1987),
and/or a family history of disease (e.g., Go et al. 1983;
Valle et al. 1998). Identifying genetically loaded indi-
viduals in this manner will continue to be an attractive
approach for disease-marker association studies, in par-
ticular. Risch and Teng (1998) showed that affected in-
dividuals with at least one affected sibling carried more
copies of the disease allele, on average, than did sin-
gleton cases, resulting in increased power of association
tests when cases with affected sibs are chosen for study.
Selecting individuals with multiple affected family
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members is effective in part because chromosomes that
occur in multiple affected individuals are more likely to
carry disease alleles. An even more effective approach
to obtaining a case sample enriched for genetic risk fac-
tors may be to select individuals that carry these shared
chromosomes. Allele-sharing information could be used
to identify families showing excess allele sharing in a
region of interest and/or the individuals within each
family who show the most allele sharing with other
affected family members. By carefully selecting families
and/or individuals on the basis of increased allele shar-
ing, we might increase the frequency of the disease-
associated allele in the case sample and thereby increase
the power of association studies. Using allele-sharing
information may also be a more efﬁcient use of geno-
typing resources. In addition to deﬁning a potentially
more informative sample, a strategy that uses individ-
uals only from the families with excess allele sharing
requires fewer individuals be genotyped. Given ﬁxed
genotyping resources, this allows more markers to be
screened for association, providing a more dense cov-
erage of a region.
Evidence for linkage to a region of interest in the
overall sample is not required to use allele-sharing in-
formation to select cases. However, the application of
a case-selection approach that uses allele-sharing infor-
mation is most natural in the context of a linkage can-
didate region, where the case and control samples may
be derived from families in the linkage sample, inde-
pendent samples, or a combination of the two. In the
case of sibship designs, perhaps the simplest (and often
the default) approach is to type one or more randomly
selected affected individuals from each sibship in the
linkage sample along with a set of suitably chosen con-
trols. Although this is certainly reasonable, we might
obtain a more informative sample for detecting disease-
marker association by exploiting the evidence for link-
age to the region.
Selecting families that show evidence for linkage to
a region for further study has been suggested and im-
plemented previously in the context of linkage candidate
regions (e.g., Horikawa et al. 2000; Van Eerdewegh et
al. 2002; Kim et al. 2003), but the properties of the
approach have not been evaluated systematically. Davis
et al. (2001) used information from multiple covariates
to identify families that contributed to the evidence for
linkage to the region for further study. In contrast, to
our knowledge, using allele-sharing information to se-
lect individuals within each family who show maximal
sharing with other affected individuals is a new ap-
proach and has been neither applied nor described.
In this article, we compare three case-selection strat-
egies that use allele-sharing information with a strategy
that selects a single individual from each family at ran-
dom when affected sibships have been collected for
study. Speciﬁcally, we compare the strategies in terms
of statistics of the form , where and2 2ˆ ˆ ˆ ˆˆ(p  p ) /j p pa u a u
are the estimated marker allele frequencies in the af-
fected cases and unaffected controls, respectively, and
is the estimated SD of the difference. Because an in-jˆ
crease in due to selection of sibships may resultˆ ˆp  pa u
in a sample size reduction that increases , we investi-jˆ
gate whether the increase in is enough to com-ˆ ˆp  pa u
pensate for the loss in sample size. We evaluate multiple
disease models, varying the frequency of the disease-
predisposing variant and its impact on disease risk. We
show that enriching the case sample for alleles that are
shared by multiple affected individuals can increase the
power and genotyping efﬁciency of case-control studies
in the context of affected sibship designs. We show that
this is true even when the power to detect linkage to a
region in the entire sample is negligible.We also describe
how the approach might be extended to more general
pedigree structures, quantitative traits, and DNA pool-
ing studies.
Methods
We consider the problem of selecting a set of unrelated
cases (one per family) from a set of sibships, each with
two or more affected individuals. These cases could then
be genotyped and used to evaluate evidence for associ-
ation in a typical case-control setting. (See the “Discus-
sion” section for comments on markers typed inmultiple
affected individuals per family.) Our goals are to choose
individuals who maximize the expected allele-frequency
difference between cases and controls and to use ge-
notyping resources efﬁciently.
Deﬁnitions and Assumptions
By either ignoring or using allele-sharing information
in choosing affected sibships and affected individuals
within those sibships, we consider four case-selection
strategies: (i) one sib randomly chosen from each sibship
(“all-random,” or AR), (ii) one sib with the most evi-
dence for sharing with other sibs chosen from each sib-
ship (“all-best,” or AB), (iii) one sib randomly chosen
only from sibships with evidence for linkage (“linked-
random,” or LR), and (iv) one sib with themost evidence
for sharing with other sibs chosen only from sibships
with evidence for linkage (“linked-best,” or LB).
For simplicity, we assume that a sample of unrelated,
unaffected individuals well matched to the case individ-
uals is available to serve as controls. Let p be the pop-
ulation allele frequency of the disease-predisposing var-
iant D, and let . Let pa and pu be the frequencyq p 1 p
of D in affected cases and unaffected controls, respec-
tively, and let paFSS be the expected frequency of D in
cases selected by strategy . Simi-SS  {AR,AB,LR,LB}
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Table 1
Sibship IBD Conﬁgurations
No. of Affected Sibs
and Conﬁguration NPLpairs
a NPLall
a
Best
Sib(s) Pr0
b
2:
13 13   13 .250
13 14 0 0 13 14 .500
13 24   13 24 .250
3:
13 13 13   13 .063
13 13 14   13 .375
13 13 24   13 .188
13 14 23   13 .375
4:
13 13 13 13   13 .016
13 13 13 14   13 .125
13 13 14 14   13 14 .094
13 13 13 24 0  13 .063
13 13 14 23 0  13 .188
13 13 14 24   13 14c .375
13 13 24 24   13 24 .047
13 14 23 24   Any .094
5:
13 13 13 13 13   13 .004
13 13 13 13 14   13 .039
13 13 13 14 14   13 .078
13 13 13 13 24   13 .020
13 13 13 14 23   13 .078
13 13 13 14 24 0  13 .156
13 13 14 14 23 0  13 .234
13 13 13 24 24   13 .039
13 13 14 24 24   14 .117
13 13 14 23 24   13 .234
NOTE.—Alleles 1 and 2 are maternal, and alleles 3 and 4
are paternal.
a IBD conﬁguration has NPL score less than (), equal to
(0), or greater than () 0.
b Probability of IBD conﬁguration under the null hypoth-
esis of no linkage.
c The 13 genotype has the highest Spairs(j) score, and the
14 genotype has the highest Sall(j) score.
larly, let be the expected difference in the disease-DpSS
allele frequency between cases and controls and NSS be
the expected number of cases for strategy SS. For sim-
plicity, we assume that the number of controls, N, is
equal to the number of affected sibships, so that N p
.N p N  N p NAR AB LR LB
We consider one-locus, two-allele disease models with
penetrances , populationf p Pr (DiseaseFi copies of D)i
prevalence and attributable2 2K p q f  2pqf  p f0 1 2
fraction . For dominant, additive, andAF p (K f ) /K0
recessive models, setting K, AF, and p completely spec-
iﬁes the disease model. By deﬁnition, .f p K(1 AF)0
For dominant models, .2 2f p f p (K q f ) / (1  q )1 2 0
For additive models, andf p (f  f ) /2 f p (K1 0 2 2
. For recessive models, andqf ) /p f p f f p [K0 1 0 2
. The genotype relative risk associatedwith2 2f (1 p )] /p0
having i copies of the disease allele compared with 0
copies is .GRR p f /fi i 0
Selecting Sibships on the Basis of Allele Sharing
To identify sibships showing evidence for linkage, we
use identity-by-descent (IBD) sharing scores. Several
such scores have been proposed, with the goal of iden-
tifying families that demonstrate excess allele sharing
consistent with linkage (e.g., Whittemore and Halpern
1994; McPeek 1999; Sengul et al. 2001). Regardless of
which score, S, is chosen, the conditional expected shar-
ing score (given the marker data for the affected sibship),
Si, is calculated for each sibship i and standardized under
the null hypothesis of no linkage. We deﬁne a sibship
as showing evidence for linkage if the standardized shar-
ing score for the sibship is (i)NPL p [S E (S)]/SD (S)0 0
strictly 10, corresponding to more IBD sharing than ex-
pected under no linkage or (ii) 0, which excludes only
those families with less sharing than expected under no
linkage. The ﬁrst deﬁnition requires clear excess allele
sharing but results in a smaller sample than does the
second deﬁnition. Here, E0(S) and SD0(S) represent the
mean and standard deviation of the sharing score S un-
der no linkage.
We employ the scores Spairs and Sall (Whittemore and
Halpern 1994). Spairs measures pairwise IBD allele
sharing among all affected members of a family. In
the case of sibships, Spairs can be written as S ppairs
, where is the estimated proportion ofˆ ˆ p(i,j) p(i,j)!i j
alleles shared IBD by sibs i and j, and the sum is taken
over all sib pairs in the sibship. The alternative(i,j)
score, Sall, gives more weight to sibships in which mul-
tiple sibs share the same allele IBD. Sall is deﬁned as
, where h is one of the 2s pos-4sS p 2  [ b (h)!]all kh kp1
sible sets of alleles generated by choosing one allele from
each of the s affected sibs within the sibship, and b (h)k
is the number of times parental allele k appears in h.
For sib pairs and trios, Sall is equal to Spairs after stan-
dardization (Sengul et al. 2001).
Selecting Individual Sib(s) with the Most Evidence
for Sharing with other Affected Sibs
Once a sibship has been chosen for inclusion (either
because all families will be included or on the basis of
allele sharing), we next choose which individual from
that sibship to include. We deﬁne the sib-speciﬁc Spairs
score for sib j as , where the sumˆS (j) p  p(i,j)pairs i(j
is taken over only those sib pairs that include sib j.
Similarly, we deﬁne a sib-speciﬁc Sall score as S (j) pall
, where the product is over only the2s2  [ b (h)!]kh kp1
two alleles of sib j instead of over all four parental alleles.
We identiﬁed the sib(s) with the highest sib-speciﬁc shar-
ing score as the “best” sib(s). For sib pairs, both sibs
Fingerlin et al.: Case Selection Based on Allele Sharing 435
have the same sharing score, and so there is no difference
between the “best” and “random” strategies.
Table 1 displays the parental allele assignments that
correspond to unique IBD conﬁgurations for sibship
sizes –5 (Sengul et al. 2001). Columns 2 and 3s p 2
indicate whether the NPLpairs and NPLall scores for each
conﬁguration are greater (), less than (), or equal to
(0) 0. Column 4 indicates which sibs have the highest
sib-speciﬁc sharing score for each conﬁguration. For all
conﬁgurations but one, the sib-speciﬁc Spairs(j) and Sall(j)
scores select the same sib(s). As a speciﬁc example, table
2 displays the sibship Spairs score, sib-speciﬁc Spairs(j)
scores, and expected disease-allele frequencies under a
disease model for each unique IBD conﬁguration for an
affected sib trio.
Comparison of Selection Strategies
To compare the strategies, we considered three cri-
teria. First, we computed and the pro-Dp p p  pSS aFSS u
portional increase in DpSS for each of the allele sharing–
based strategies (AB, LR, and LB) compared with the
AR strategy (e.g., ). Second, as a mea-[Dp  Dp ] /DpAB AR AR
sure of the relative power of the selection strategies, we
computed the ratios of the test statistics for each of the
strategies to the statistic for the AR strategy (e.g.,
). We considered test statistics of the form2 2T /TAB AR
2
ˆ ˆ(p  p )aFSS u2T p .SS ˆ ˆ ˆ ˆp (1p ) p (1p )aFSS aFSS u u2N 2NSS
These statistics follow a x2 distribution asymptotically
and increase linearly with sample size. Third, we com-
puted the per-genotype contribution to each test statistic
as , as a measure of the informative-2I p T /(N N)SS SS SS
ness of the selected individuals, and computed the ratios
of the per-genotype contributions (e.g., ) to com-I /IAB AR
pare the efﬁciency of the strategies in terms of use of
genotyping resources.
Case Disease-Allele Frequencies when IBD Is Known:
Analytic Calculations
We initially considered the situation in which IBD at
the disease locus is known. For affected sibships of size
–5 and for each SS and disease model, we calcu-s p 2
lated the expected value of the disease-allele frequency
p in the affected sib selected for genotyping, , un-p (s)aFSS
der a given disease model as
1
p (s) p n Pr (vFs affected sibs) , (1)aFSS DFSS2 v
where nDFSS is the expected number of copies of D in the
individual selected by strategy SS for inheritance vector
v, and the sum is taken over all possible inheritance
vectors for a sibship of size s. An inheritance vector
speciﬁes the grandparental origin of each allele in a sib-
ship and therefore captures the IBD information for the
sibship. To calculate the allele frequency for sibships
selected on the basis of allele sharing, we restrict the
sum in equation (1) to inheritance vectors in L p
or . Similarly, the pro-{v :NPL(v) 1 0} {v :NPL(v)  0}
portion of sibships included for the two “linked” strat-
egies can be written as . Let gf Pr (vFs affected sibs)Lv
and gm be the ordered genotypes for the father and
mother, respectively, and let , , and bePr (g ) Pr (g ) Pr (v)f m
the prior probabilities of gf, gm, and v.
Since
Pr (s affected sibsFv) Pr (v)
Pr (vFs affected sibs) p ,Pr (s affected sibsFw) Pr (w)
w
Pr (saffected sibsFv)
p Pr (g ) Pr (g ) Pr (saffected sibsFv,g ,g ) f m f m
g gf m
s
p Pr (g ) Pr (g ) Pr (sib jaffectedFv,g ,g ) , f m f m
jp1g gf m
and for all v,sPr (v) p 4
Pr (vFsaffected sibs)
sPr (g ) Pr (g )  Pr (sib jaffectedFv,g ,g )f m f m
g g jp1f mp .sPr (g ) Pr (g )  Pr (sib jaffectedFw,g ,g )f m f m
w g g jp1f m
The terms are simple functionsPr (sib j affectedFv,g ,g )f m
of the penetrance functions fi.
We calculated paFSS(s) for models with prevalence
–.10 at .01 intervals, –1 at .05 inter-K p .01 AF p .05
vals, and disease-allele frequency –.9975 atp p .0025
.0025 intervals. Because of our interest in complex dis-
eases, we focus our attention on models for which the
genotype relative risk . We also repeated theGRR  32
calculation of paFSS(s) for each SS under the assumption
that the sibship included 1 or 2 unaffected sibs in ad-
dition to the –5 affected sibs.s p 2
Case Disease-Allele Frequencies when IBD Is
Unknown: Simulation
Since IBD is generally not known with certainty for
studies of affected sibships, we performed computer sim-
ulations to compare the four case-selection strategies
when the IBD status of the sibs is incompletely known
because of partially informative markers and missing
parental genotypes. Table 3 describes the one-locus, two-
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Table 2
Spairs, Sib-Speciﬁc Spairs(j), and Disease-Allele Frequencies with Three Affected Sibs
SIB CONFIGURATION
Spairs Spairs(A) Spairs(B) Spairs(C) pa(A) pa(B) pa(C) Pr(ConﬁgurationFModel)Sib A Sib B Sib C
13 13 13 3 2 2 2 .40 .40 .40 .067
13 13 14 2 1.5 1.5 1 .37 .37 .33 .384
13 13 24 1 1 1 0 .33 .33 .26 .183
13 14 23 1 1 .5 .5 .33 .29 .29 .366
NOTE.—Additive disease model: , , and , corresponding to , , andK p .10 AF p .15 p p .20 f p .0850 f p .12250 1
.f p .16002
Table 3
Characteristics of Simulated Disease Models
Model K AF p GRR2 ls
I:
Dominant .10 .20 .15 1.9 1.1
Additive .10 .20 .15 2.7 1.1
Recessive .10 .20 .15 12.1 1.5
II:
Dominant .10 .50 .25 3.3 1.1
Additive .10 .50 .25 5.0 1.2
Recessive .10 .50 .25 17.0 2.3
III:
Dominant .11 .54 .35 3.0 1.1
Additive .09 .41 .35 3.0 1.1
Recessive .09 .20 .35 3.0 1.1
NOTE.—Additional settings were considered for
analytical calculations.
allele disease models we considered. We chose these
models to examine the properties of the strategies over
a range of values of AF, p, GRR2, and sibling recurrence
risk ratio, ls, when each of these characteristics was held
constant.
For each of the disease models in table 3, we generated
1,000 replicate samples of 500 affected sibships with
–4 affected sibs. We assumed a 100-cM map ofs p 2
markers with four equally frequent alleles ( )H p .75
evenly spaced at a 5- or 1-cM density, with the disease
locus centered between two markers in the middle of
the map. We used the Haldane (1919) no-interference
map function to convert map distances to recombination
fractions. We generated parental chromosomes on the
basis of the population allele frequencies and under the
assumption of Hardy-Weinberg and linkage equilibrium,
and we generated offspring chromosomes allowing for
recombination according to the genetic map. We deter-
mined whether each individual was affected on the basis
of the penetrance function for his/her genotype and kept
only those sibships with all siblings affected. For linkage
analyses, we removed the disease locus genotypes and
all parental genotypes.
We calculated the Kong and Cox (1997) LOD scores
for the entire sample and for each sibship through use
of the Merlin software package (Abecasis et al. 2002;
Merlin Web site). Since it is typical to examine regions
near modest linkage peaks in complex disease genome
scans, we initially simulated samples until we had 1,000
replicates with maximum LOD score (MLS)1.We also
performed the simulations with no minimum threshold
requirement for the MLS. For each replicate, we based
the selection of cases on allele sharing information at
the position of the MLS and then also at the true disease-
locus position. This procedure allowed us both to mimic
a typical follow-up study and to compare selection at
the MLS to that at the true position. Because the dis-
tribution of NPLpairs scores is not discrete when IBD is
estimated rather than known, capturing families that
have scores near that expected under no linkage (equiv-
alent to IBD-known NPLpairs scores of 0) requires using
a cutoff that is slightly !0 for sibship sizes 2 and 4. We
investigated several such cutoffs and found that results
were very similar when selection was based on a cutoff
between 0.25 and 0.45, and we report results based
on a cutoff of 0.35.
Results
IBD Known at Disease Locus: Analytic Calculations
In what follows, we give the results for selection based
on Spairs and sib-speciﬁc Spairs(j) scores and note differ-
ences associated with using the Sall and Sall(j) scores. Fig-
ure 1 shows the results for each comparison criterion
for additive models with a . Results were sim-GRR  32
ilar for dominant and recessive models (see ﬁgs. A and
B [online only]).
Proportion of Sample Size Retained for “Linked”
Strategies
Under the null hypothesis of no linkage, 25% of sib
pairs have NPLpairs 10. The corresponding proportions
are 44%, 23%, and 22% for sibships with , 4,s p 3
and 5 affected sibs, respectively. For NPLpairs 0, these
proportions are 75%, 44%, 48%, and 61%. Given link-
age, these proportions are increased. Despite these in-
creases, for most of the disease models we considered,
unless the sibship sample is sufﬁciently large that25%
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Figure 1 Additive models with GRR2 3, mean 2 SD. A, Proportional increase in disease-allele frequency difference for sharing-based
strategies compared with the AR strategy. B, Ratio of test statistics for sharing-based strategies to test statistic for the AR strategy. C, Ratio
of per-genotype information for sharing-based strategies to per-genotype information for the AR strategy.
of the sample provides adequate power, the reduction in
sample size for the NPLpairs 10 selection outweighs any
increase in the disease-allele frequency for the two
“linked” strategies for sibship sizes of 2, 4, and 5. Hence,
we give results for the less restrictive NPLpairs 0 selec-
tion for the remainder of this article, unless otherwise
noted.
Difference in Disease-Allele Frequency between Cases
and Controls
The expected difference in the disease-allele frequency
between cases and controls, , is increased for the twoDp
“best” strategies compared with the AR strategy for
every disease model in which AF is !.95. In addition,
with the exception of dominant models with forp 1 .98
sibs, is greater for the LR strategy than for thes p 5 Dp
AR strategy for all models with GRR23. It is surprising
that the LR strategy becomes less useful as the GRR2
increases. Still, disease models with for3 ! GRR  102
which decreases for the LR strategy are generallyDp
limited to models with large AFs (190% have AF 1.50).
Regardless of selection strategy, the mean expected
disease-allele frequency difference between cases and
controls increases with sibship size (data not shown).
Within each sibship size, the largest average is seenDp
for the LB strategy. Table 4 gives speciﬁc examples of
how the disease frequency increases when the case group
is enriched for cases with additional affected family
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Table 4
Disease-Allele Frequency in Controls and Selected Case Groups
p AND
MODEL
FREQUENCY IN GROUP
Control
Singleton
Case
ASP
Case
Linked
ASP
Case
Affected
Trio
Case
Affected
Trio Best
Case
Linked
Affected
Trio Case
Linked
Affected Trio
Best Case
.20:
Dominant .194 .253 .282 .291 .309 .324 .333 .341
Additive .193 .260 .295 .306 .331 .348 .361 .371
Recessive .187 .320 .467 .506 .646 .690 .750 .778
.50:
Dominant .497 .525 .536 .540 .547 .553 .556 .559
Additive .496 .538 .556 .562 .574 .583 .589 .595
Recessive .492 .575 .618 .631 .662 .681 .697 .709
NOTE.— ; .K p .10 AF p .15
members and evidence for sharing with other affected
siblings for several models with disease prevalence
and . Although the absolute increasesK p .10 AF p .15
in can be small, the proportional increases in areDp Dp
meaningful (ﬁg. 1A). The proportional increase in isDp
largest for small values of AF and GRR2.
Relative Power of the Selection Strategies
Across every disease model considered, the expected
test statistic for the AB strategy was greater than that
for the AR strategy, since was increased without re-Dp
ducing the sample size. For many models, the expected
test statistic of the LB strategy was also increased com-
pared with the AR strategy while requiring fewer ge-
notypes. With the exception of dominant models for
sibships with or 4 affected sibs, the average ratios p 3
of the test statistics comparing the LB strategy with the
AR strategy is1 for models with GRR23. In contrast,
the mean ratios for the dominant models are 0.90
and for 3 and 4 affected sibs, respectively..06 0.95 .05
For sibship sizes –5, the test statistic for the LRs p 3
strategy was reduced, on average, compared with the
AR strategy, since the increase in was insufﬁcient toDp
outweigh the loss in sample size. The increases in the
test statistics associated with the two “best” strategies
indicate that these two strategies have greater power, on
average, than the AR strategy. The magnitudes of these
increases necessarily vary by disease model.
For additive models, the AB strategy has the greatest
power for sibship sizes –5 and is associated withs p 3
an average , , and in-26% 1% 21% 1% 31% 1%
crease in the test statistic compared with the AR strategy,
for sibship sizes of 3, 4, and 5, respectively (ﬁg. 1B).
Recall that the AB and AR strategies are equivalent for
2 sibs. The corresponding average increases in the test
statistic for the LB over the AR strategy for additive
models are , , , and5% 1% 2% 5% 7% 5%
for sibship sizes 2, 3, 4, and 5, respectively.19% 3%
The ability to type fewer individuals on each marker
allows more markers to be typed, which, in turn, pro-
vides better coverage of the region. Given ﬁxed geno-
typing resources, for additive models with GRR2 3,
∼14%, 38%, 34%, and 24% more markers could be
typed, on average, for 2, 3, 4, and 5 sibs, respectively,
using the LB strategy as opposed to the AR strategy,
while maintaining or increasing power. Since the pro-
portion of sibships selected under each of the disease
models is similar, the potential increase in the number
of markers typed is similar for dominant and recessive
models.
Relative Per-Genotype Information Gain
Each of the three sharing-based strategies is more ef-
ﬁcient in the per-genotype contribution to the test sta-
tistic than the AR strategy. The LB strategy is the most
efﬁcient strategy, with an average 20%, 41%, 43%, and
47% larger per-genotype contribution to the test statistic
than the AR strategy for additive models with GRR23
for sibship sizes of 2, 3, 4, and 5, respectively (ﬁg. 1C).
These results suggest that, if genotyping costs are the
limiting factor for a study, the LB strategy is the most
efﬁcient use of genotyping resources.
Unaffected Sibs in Sibship
When we assume that the sibship includes either 1 or
2 unaffected sibs in addition to s affected sibs, results
are very similar. For all models with GRR2 3, the dis-
ease-allele frequency in chosen affected sibs is lower than
when we assume no affected siblings. At the same time,
the proportional increase in achieved by using theDp
linkage-based strategies is slightly greater (on the order
of 0.5%–1.5%), on average, compared with sibships
with no unaffected sibs.
Differences between Spairs and Sall
The results described above are for selection of sib-
ships and sibs on the basis of the Spairs and Spairs(j) sta-
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Table 5
Mean Proportional Increase in Disease-Allele Frequency Difference
when IBD Status Is Unknown
MODEL AND
SIMULATION
CONDITIONa
MEAN PROPORTIONAL INCREASE IN
DISEASE-ALLELE FREQUENCY DIFFERENCE FOR
2 Affected
Sibs
3 Affected
Sibs
4 Affected
Sibs
AB LR LB AB LR LB AB LR LB
Model I:
Expected .00 .11 .11 .13 .22 .29 .11 .14 .27
Actual, all .00 .11 .11 .13 .22 .29 .11 .13 .26
Actual, MLS 1 .00 .11 .11 .13 .21 .28 .10 .13 .25
1 cM .00 .09 .09 .12 .18 .26 .10 .12 .24
5 cM .00 .09 .09 .11 .16 .23 .10 .09 .21
Model II:
Expected .00 .08 .08 .11 .13 .18 .09 .07 .18
Actual, all .00 .08 .08 .11 .12 .18 .09 .07 .17
Actual, MLS 1 .00 .08 .08 .11 .12 .18 .09 .07 .17
1 cM .00 .07 .07 .10 .11 .17 .08 .06 .17
5 cM .00 .06 .06 .10 .10 .16 .09 .05 .15
Model III:
Expected .00 .09 .09 .12 .16 .22 .09 .09 .20
Actual, all .00 .09 .09 .11 .15 .22 .09 .09 .20
Actual, MLS 1 .00 .09 .09 .12 .15 .22 .09 .09 .20
1 cM .00 .08 .08 .11 .13 .20 .09 .08 .19
5 cM .00 .07 .07 .10 .11 .18 .09 .06 .16
a Expected p selection based on analytic calculation when IBD
known; Actual, all p selection based on the true disease-locus position
with data generated at 1-cM marker density and analyzed every 0.5
cM, no minimum MLS; Actual, MLS 1 p selection based on the
true disease-locus position with data generated at 1-cMmarker density
and analyzed every 0.5 cM, MLS 1; 1 and 5 cM p selection based
on position of MLS 1 with data generated at 1- and 5-cM marker
density, respectively, and analyzed every 0.5 cM.
tistics, respectively. Results are very similar for selection
based on Sall and Sall(j). Recall that NPLpairs and NPLall
are identical for sib pairs and trios. For sibships with 4
or 5 affected sibs, the proportional increase in inDp
the more restrictive NPLall selection is not enough to
outweigh the loss in sample size when testing for
association.
IBD Unknown at Disease Locus: Simulation
Table 5 shows the mean proportional increase in Dp
for each of the strategies compared with the AR strategy
for NPLpairs selection, for each of the additive models we
considered. Table 6 similarly shows the mean ratios of
the test statistics. Each table includes the mean propor-
tional increase or ratio based on the IBD-known analytic
calculation and based on selection at the true disease-
locus position for simulations in which we required no
minimum MLS. Each table also includes selection based
on the true position of the disease locus and the position
of the MLS for 1- and 5-cM marker spacing for the
simulations in which we required an MLS 1. Many
modest linkage signals may be false, and no strategy will
legitimately improve the evidence for association in this
case. To examine the situation in which these peaks are
indicative of a true linkage signal, we restricted our re-
sults based on the MLS position in both tables to those
with an MLS 1 within 10 cM on either side of the true
disease-locus position. Results were nearly identical
when we used all replicates with an MLS 1 within 20
cM on either side of the true position.
We ﬁnd that each of the strategies performs very sim-
ilarly to expectations based on the IBD-known case for
these additive models and for the dominant and recessive
models (data not shown). These results highlight the fact
that, even in cases in which the power to detect linkage
is negligible in the entire sample, using allele-sharing
information within a reasonable distance of the disease-
locus position to choose families and individuals can
increase the power to detect association. Aside from
showing that selection based on the MLS is nearly as
good as that based on the true disease-locus position,
the results based on the true position are relevant for
candidate gene studies, in which selection may be based
on the position of the putative disease gene rather than
the MLS and can be performed in the absence of an
interesting MLS value.
Discussion
We considered four case-selection strategies when af-
fected sibships have been collected. Each strategy uses
one affected individual from each sibship and compares
these cases with a sample of unrelated controls. We
found that the case sample could be enriched for the
disease allele by choosing the affected sib that showed
the most evidence for pairwise sharing with the other
affected sibs in the sibship. When a “best sib” was cho-
sen from each of the sibships in the linkage sample (i.e.,
the AB strategy), the test statistic was greater than the
AR test statistic for all disease models considered and
was increased by 120%, on average. This increase in-
dicates that the power to detect association is increased
over a broad range of disease models compared with
randomly choosing one sib. When the best sib was cho-
sen only from sibships showing evidence for linkage (i.e.,
the LB strategy), the magnitude of the test statistic was
generally maintained compared with randomly choosing
one sib from each of the sibships, whereas the number
of individuals genotyped per marker was reduced. Given
ﬁxed genotyping resources, this decrease in the sample
size allows more markers to be typed in a region.
Even though we selected the best sib with a mode-
of-inheritance–free statistic, the best sib often had the
most copies of the disease allele in the sibship. In cases
in which the sib with the most copies was not chosen
(e.g., more than one sib with same sharing score but
different genotypes), the loss of information was min-
imal. If the full parametric disease model were known,
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Table 6
Mean Ratio of Test Statistics when IBD Status Is Unknown
MODEL AND
SIMULATION
CONDITIONa
MEAN TEST STATISTIC RATIO FOR
2 Affected Sibs 3 Affected Sibs 4 Affected Sibs
AB LR LB AB LR LB AB LR LB
Model I:
Expected 1.00 1.01 1.01 1.24 .83 .91 1.21 .80 .98
Actual, all 1.00 .99 .99 1.25 .82 .91 1.21 .80 .99
Actual, MLS 1 1.00 .99 .99 1.24 .83 .92 1.20 .80 .99
1 cM 1.00 .99 .99 1.23 .82 .92 1.19 .81 .97
5 cM 1.00 .96 .96 1.21 .79 .89 1.20 .82 1.00
Model II:
Expected 1.00 1.01 1.01 1.26 .86 .97 1.23 .83 1.06
Actual, all 1.00 1.00 1.00 1.26 .84 .95 1.22 .83 1.07
Actual, MLS 1 1.00 .99 .99 1.26 .84 .95 1.22 .83 1.06
1 cM 1.00 .98 .98 1.25 .84 .95 1.21 .83 1.05
5 cM 1.00 .95 .95 1.23 .81 .92 1.22 .84 1.06
Model III:
Expected 1.00 1.03 1.03 1.26 .88 1.00 1.22 .84 1.07
Actual, all 1.00 1.02 1.02 1.26 .87 .99 1.22 .85 1.08
Actual, MLS 1 1.00 1.02 1.02 1.27 .88 1.00 1.22 .85 1.09
1 cM 1.00 1.01 1.01 1.25 .88 1.00 1.21 .85 1.07
5 cM 1.00 .97 .97 1.23 .85 .97 1.21 .87 1.08
a Expected p selection based on analytic calculation when IBD known; Actual, all p
selection based on the true disease-locus position with data generated at 1-cM marker
density and analyzed every 0.5 cM, no minimum MLS; Actual, MLS 1 p selection
based on the true disease-locus position with data generated at 1-cM marker density and
analyzed every 0.5 cM, MLS 1; 1 and 5 cM p selection based on position of MLS 1
with data generated at 1- and 5-cM marker density, respectively, and analyzed every 0.5
cM.
the average proportional increase in would changeDp
by a factor of 1.024 (.017), 1.007 (.008), and 1.002
(.002) over all of the dominant, additive, and reces-
sive models considered with , respectively, forK p .10
the AB strategy. Results were very similar for the LB
strategy. Hence, our best-sib selection is nearly as good
as selection based on the (unknown) underlying mode
of inheritance.
Each of the sharing-based strategies was more efﬁ-
cient than the AR strategy, in terms of per-genotype
information gain. The LB strategy was the most efﬁcient
over a broad range of disease models and was, on av-
erage, 20%–47% more efﬁcient than the AR strategy
for additive models with a GRR2 3 and was 17%–
32% and 23%–55% more efﬁcient for dominant and
recessive models, respectively.
Practical Considerations
These results suggest that the choice between strategies
will depend on the characteristics of the underlying sam-
ple. For affected sibships of size 2, the two equivalent
“linked” strategies have similar power to the “all” strat-
egies and are, on average, 17%–23% more efﬁcient, in
terms of per-genotype information, compared with the
“all” strategies. For sibships of size 3–5, if having max-
imum power to detect association with a particular
marker is of primary concern, then the AB strategy is
preferred, since it results in the largest mean test statistic
of all the selection strategies. If, however, the power as-
sociated with the LB strategy is deemed sufﬁcient for a
given sample and allocation of resources is of primary
concern, then the LB strategy is superior, since it allows
more markers to be genotyped.
Even if the decision is made to genotype sibs from all
of the sibships in the linkage sample, either of the two
“linked” strategies can be performed as an interesting
subanalysis. Since we do not expect the “linked” case
group to have greater power than the entire case group,
the objective of these analyses would likely be to see
whether the estimated frequency of the putative disease
allele was greater in the “linked” group for a given
marker. For the additive simulation models, we saw an
increase in the frequency of the disease allele in 195%
of the replicate data sets for sib pairs when selection of
the linked sibships was based on the position of an MLS
within 10 cM on either side of the true disease locus.
We performed a similar simulation for an even more
modest additive model: , , andl p 1.02 GRR p 1.9s 2
. In this case, the disease-allele frequency in-Dp p 12%
creased in 67% of the replicates when selection was
based on the position of the MLS and in 83% of rep-
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licates when selection was based on the true position of
the disease locus. Hence, such an increase for a given
marker is evidence in support of that marker being rel-
evant to disease status, but the absence of such an in-
crease does not necessarily indicate that the marker is
unrelated to disease.
We note that we have assumed that the goal of the
association studies considered here is to identify disease-
predisposing variants rather than to carefully character-
ize their impact on disease risk in a speciﬁc population.
Certainly, population-based samples of cases and con-
trols are necessary for such characterization, and any
sample selected to enrich for disease-predisposing vari-
ants is inappropriate for that purpose. We also note that
the three sharing-based strategies do require that region-
speciﬁc genotyping sets be created when more than one
region is of interest. Whether this poses a problem for
a particular lab will depend on the scale of the project
and available technical resources.
Alternative Study Designs
There are several alternatives to a study design that
uses one individual each from affected sibships and com-
pares those cases to unrelated controls. For case-control
studies, cases may be singleton cases or those with other
affected family members. Although it is often simpler
and less expensive to collect singleton cases, cases with
affected relatives can provide a more powerful sample
for association even when only one of the sibs from each
family is genotyped (Risch and Teng 1998). The increase
in power is largely due to the increase in the expected
disease-allele frequency in individuals from families with
multiple affected individuals rather than to the increased
sample size achieved when multiple sibs are included in
an analysis.
If multiple sibs have been genotyped for a given
marker, it is best to use all of those sibs in analyses, since
this generally results in more-efﬁcient estimates of the
disease-allele frequency and, hence, more-powerful tests
(see, e.g., Li and Boehnke 2001). This is clearly the case
for those markers used to assess allele-sharing infor-
mation, and methods that appropriately account for the
correlation among related cases are available for this
situation (Slager and Schaid 2001). We considered the
case in which one sib per family would be typed in the
follow-up association study, since, given ﬁxed genotyp-
ing resources and large regions of interest, many inves-
tigators initially type many markers in only one sib per
family. Genotyping all affected individuals in each family
would be more powerful but perhaps not as cost effec-
tive. Although beyond the scope of this article, it would
certainly be useful to compare the cost efﬁciency of a
design that uses all available affected family members
with the design strategies investigated here.
An alternative to using unrelated controls is to use
family-based sibling controls (Boehnke and Langefeld
1998; Spielman and Ewens 1998; Abecasis et al. 2000;
Martin et al. 2000). Although our strategies are not lim-
ited to using unrelated controls, we chose to use unre-
lated controls because, in most cases, tests that use sib-
ling controls are much less powerful (Boehnke and
Langefeld 1998; Risch and Teng 1998). In addition, the
potential increase in the contrast between cases and con-
trols that is due to careful selection of sibships is limited,
because the frequency of the disease allele may be in-
creased in the unaffected as well as the affected sibs. For
investigators who do not have a sample of unrelated
controls, the AB strategy is likely preferred, since the
case sample can be enriched for the disease allele without
correspondingly increasing the frequency of the disease-
allele in the unaffected sibling control.
Extensions
We may extend this work in several ways. First, we
assumed that only affected sibs were used in the selection
of the best sib. If unaffected sibs have also been collected
and typed on the markers used for measuring allele-
sharing, it should be possible to use these sibs to choose
between affected sibs with the same sharing score. If two
or more sibs have the same sharing score but different
genotypes, then the sib(s) that share the fewest alleles
with the unaffected sibs should be more likely to be
carrying the disease allele. The choice between sibs with
the same sharing score also could be based on other
factors, such as disease severity or age at onset.
Second, several investigators have suggested using
pools of multiple DNA samples for genotyping, rather
than individuals, as a screening tool in the ﬁrst phase of
an association study (e.g., Arnheim et al. 1985; Barcellos
et al. 1997; Wolford et al. 2000; Mohlke et al. 2002).
This approach reduces the number of genotypes that
need to be determined but introduces measurement error
associated with creating the pools and estimating the
allele frequency in the pools. If we assume that the error
due to pooling in the allele frequency estimate is constant
across sample sizes, then the sampling variability is the
only component of variance that increases for the two
“linked” strategies. Whether the LB or AB strategy
would be optimal will depend on the relative magnitude
of the pooling variance. If the pooling variance is large
compared with the sampling variance, then the LB strat-
egy may be superior, since it results in the largest increase
in the difference in frequency of the disease allele be-
tween cases and controls. If the pooling variance is pro-
portionally small, then the AB strategy is likely superior,
since it does not result in a decrease in sample size that
increases the sampling variance.
Third, these strategies could also be extended to gen-
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eral pedigrees. The principles of the strategies would
remain the same, but the choice of scoring statistic—
Spairs, Sall, or some other—might becomemore important.
Fourth, these strategies might be extended to association
studies in regions of quantitative trait linkage (Camp et
al. 2001; Sham et al. 2002). As before, the notion is that,
among sibs (or other relatives) with similar phenotypes,
those that have the most evidence for IBD sharing in a
QTL linkage region should be more likely to carry the
allele(s) that is inﬂuencing variation in that quantitative
trait.
In summary, we have compared four different case-
selection strategies, in terms of the relative magnitude of
the association test statistic and per-genotype information
gain. We found that, by selecting individuals most likely
to be carrying chromosomes shared by multiple affected
individuals, we could increase the test statistic and there-
fore improve power and increase the genotyping efﬁciency
of disease-marker association studies. These results em-
phasize the utility, in terms of power and efﬁciency of
genotyping resource allocation, of study designs that use
cases from families with multiple affected individuals.
These comparisons should be helpful to investigators
planning association studies, particularly in linkage can-
didate regions.
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